Alex Smith joins Oxeia investor webinar on concussion therapy

Oxeia Biopharmaceuticals will hold a June 18 investor webinar with former NFL quarterback Alex Smith as it promotes OXE103, an investigational treatment for persistent post-concussion symptoms. The event comes as the company says the therapy could become the first FDA-approved drug designed specifically for concussion recovery. Why it matters: - Oxeia Biopharmaceuticals is pitching OXE103 as a potential new treatment for persistent post-concussion symptoms, a condition with no FDA-approved drug therapy. - The company is trying to draw investors ahead of its next development phase and highlight a possible path to a first-in-class concussion recovery drug. What happened: - Oxeia will host a live investor webinar on June 18, 2026, from 2:00 p.m. to 2:45 p.m. EDT. - The event will feature CEO Dr. Michael Wyand, Board Member and former NFL quarterback Alex Smith, and Co-Founder and trauma surgeon Dr. Vishal Bansal. - The company says the webinar will focus on OXE103 and what it believes could become the first FDA-approved drug specifically developed for concussion recovery. - Registration is available through the webinar link . The details: - Oxeia describes OXE103 as an investigational therapy for persistent post-concussion symptoms. - The company says its development package includes a licensing agreement for Daiichi Sankyo clinical data, with nine completed studies across multiple indications and four Phase 1 safety trials. - Daiichi Sankyo’s prior ghrelin studies enrolled more than 300 patients and generated human safety and tolerability data for ghrelin, the hormone behind OXE103. - The FDA has confirmed that no additional preclinical or safety studies are required before OXE103 can advance to Phase 2b, according to the company. - Oxeia says a Phase 2a pilot study produced an 85% responder rate, compared with 33% for standard care alone. - The company says its leadership team has been part of biotechnology exits totaling about $9 billion. - Oxeia is a clinical-stage biotechnology company developing OXE103 for persistent post-concussion symptoms. - The company’s leadership has participated in exits including Arena Pharmaceuticals’ acquisition by Pfizer and Kythera Biopharmaceuticals’ acquisition by Allergan. Between the lines: - Alex Smith’s involvement gives Oxeia a prominent sports figure with personal relevance to concussion recovery, which can help the company reach both investors and a broader public audience. - The mix of prior clinical data, FDA feedback and an early responder signal suggests Oxeia is trying to position OXE103 as more de-risked than many early-stage biotech programs. - The Reg CF structure and explicit risk disclosure indicate the raise is speculative and aimed at retail investors willing to take on high uncertainty. What’s next: - Oxeia said company leadership will discuss the science behind OXE103, upcoming milestones and the regulatory path during the webinar. - The company is expected to keep advancing toward Phase 2b if development stays on track. - OXE103 remains investigational and has not been approved by the U.S. Food and Drug Administration. The bottom line: - Oxeia is using Alex Smith’s profile and a June 18 investor event to build interest in a concussion therapy program it says is closer to the FDA path than most early-stage biotech candidates.